Objectives Rheumatoid arthritis (RA), along with glucocorticoid use, is associated with cardiovascular disease. Cardiovascular safety of glucocorticoids in RA is controversial and may be related to dose and duration of use. We determined if initiating glucocorticoids in steroid-naive RA patients would increase cardiovascular event (CVE) risk in a dose and duration-dependent manner over short-term intervals.
Methods Patients enrolled in CorEvitas (formerly Corrona) RA registry. Cox proportional-hazards models estimated adjusted HRs (aHR) for incident CVE in patients who initiated glucocorticoid treatment, adjusting for RA duration, traditional cardiovascular risk factors and time-varying covariates: Clinical Disease activity Index, disease-modifying antirheumatic drugs use and prednisone-equivalent use. Glucocorticoid use assessed current daily dose, cumulative dose and duration of use over rolling intervals of preceding 6 months and 1 year.
Results 19 902 patients met criteria. 1106 CVE occurred (1.66/100 person-years). Increased aHR occurred at current doses of ≥5–9 mg 1.56 (1.18–2.06) and ≥10 mg 1.91 (1.31–2.79), without increased risk at 0–4 mg 1.04 (0.55–1.59). Cumulative dose over preceding 6 months showed increased aHR at 751–1100 mg 1.43 (1.04–1.98) and >1100 mg 2.05 (1.42–2.94), without increased risk at lower doses; duration of use over preceding 6 months exhibited increased aHR for >81 days of use 1.54 (1.08–2.32), without increased risk at shorter durations. One-year analyses were consistent.
Conclusions Over preceding 6-month and 1-year intervals, initiating glucocorticoids in steroid-naïve RA patients is associated with increased risk of CVE at daily doses ≥5 mg and increased cumulative dose and duration of use. No association with risk for CVE was found with daily prednisone of ≤4 mg or shorter cumulative doses and durations.
- Cardiovascular Diseases
Data availability statement
Data may be obtained from a third party and are not publicly available. Deidentified participant data may be obtained from CorEvitas (formerly Corrona) and are not publicly available. Reuse only with permission from CorEvitas. Contact: firstname.lastname@example.org
Statistics from Altmetric.com
What is already known about this subject?
Both rheumatoid arthritis (RA) and glucocorticoid use increase risk for cardiovascular events. There is controversy regarding the cardiovascular safety and risk of glucocorticoid use in RA patients. Effects of short-term and low-dose use are not well understood.
What does this study add?
In a large, real-word clinical registry of patients with long-standing disease, there is a daily dose, cumulative dose and duration of use glucocorticoid threshold for cardiovascular event risk in RA when analysed over short-term intervals of 6 months and 1 year.
Relative cardiovascular safety was found with <5 mg of prednisone-equivalent daily dose and lower cumulative doses and durations of use.
How might this impact on clinical practice or future developments?
Physicians should be aware of that low-dose and short-term use of glucocorticoids may increase risk of cardiovascular events when prescribing for treatment of RA in a treat-to-target approach.
Patient education of this risk threshold is essential.
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by inflammatory destructive arthritis. Risk for cardiovascular disease (CVD) in RA is increased due to high prevalence of traditional risk factors, accelerated atherosclerosis and chronic inflammation.1 Disease activity is directly related to cardiovascular risk.2 Glucocorticoids (GCs) are commonly prescribed as initial, so-called bridge, treatment for RA but are often employed for intervals that extend beyond the onset of action of other conventional, targeted synthetic or biological disease-modifying antirheumatic drugs (cs/ts/bDMARDs).3 It is often clinically challenging to taper GC. However, GCs are associated with CVD and may potentiate hypertension, hyperlipidaemia, diabetes mellitus, congestive heart failure and obesity.4–6 Given that CVD is the major comorbidity of RA,1 2 the juxtaposition of these circumstances presents a therapeutic dilemma.
Controversy exists regarding the risks and benefits of GC in RA patients. Previous small studies demonstrated an increased number of adverse events in RA patients over longer intervals with a daily prednisone-equivalent doses of >5 to 10 mg.7–10 However, debate remains regarding the detrimental cardiovascular effects of GC therapy in RA patients.11–16 Relative cardiovascular safety is generally assumed with lower dose and shorter durations of use, especially over short-term intervals. However, little data has actually been reported regarding the temporal effects of short-term interval GC use preceding cardiovascular events (CVE).
The 2016 and 2019 European League Against Rheumatism and 2015 and 2021 American College of Rheumatology (ACR) recommend the use of ‘low-dose’ GC for ‘the least amount of time’ in combination with DMARDs for the treatment of RA.3 17–19 Thus, it is important to determine the safety of initiating ‘low-dose’ GC in regard to the development of CVE. Furthermore, CVE in RA may be decreasing due to better control of disease activity following the widespread use of ts/bDMARDs, perhaps making the determination of the contribution of GC to CVE even more challenging in the present era.20
We, therefore, examined the CorEvitas (formerly Corrona) RA registry, a longitudinal database of RA patients, to determine whether there was a relationship between CVE in RA and use of GC in the dose ranges and duration of use that are consistent with published guidelines and routine clinical practice. We sought to determine the relative safety or risk for incident CVE in steroid-naïve patients who initiate ‘low-dose’ GC over short-term intervals of use based on real-world clinical observation, while adjusting for traditional cardiovascular risk factors, RA duration and disease activity and cs/ts/bDMARD use. Given the ubiquitous use of GC in this and other inflammatory conditions in a variety of dose ranges, including what is considered ‘low-dose,’ it was both timely and appropriate to reexamine this association.
Study Cohort Entry Criteria
The CorEvitas (formerly Corrona) RA registry was previously described.21 22 Inclusion criteria included age ≥18 years old and receiving a diagnosis of RA by a rheumatologist.23 Data were collected between 1 October 2001 and 31 March 2018. During this period, 48 535 patients enrolled. Exclusion criteria included: any history of current or past GC therapy at or prior to enrolment; absence of a follow-up visit; missing data for either gender, age or duration of RA; or patients that had >15 months between visits. Patients were treated per their rheumatologist without treatment assignment.
Observational data were collected from both treating physicians and patients at registry enrolment and at regular intervals consistent with the frequency of scheduled visits occurring every 2–9 months (median 4.6 months, IQR 3.60–6.24). At enrolment, detailed medical history was obtained from patients and review of medical records to accurately document lifetime comorbidities and prior treatments and medication use, including GC use.
Measure of GC use
GC use after entry into the registry was documented as equivalent milligrams of prednisone. Multiple measures of GC use were assessed. Current daily dose was defined as the most recent recorded dose at the time of a CVE or the most recent recorded dose in the registry for patients without an event. Cumulative total dose was defined as the summation of prednisone-equivalent dosage updated at each visit in a continuous, rolling manner over the preceding 6 months or 1 year (see online appendix efigure 1). Duration of use was defined as the summation of the absolute number of days a patient was treated with GC in a rolling manner over the preceding 6 months or 1 year (see online appendix efigure 1). Interval ranges for daily and cumulative dose were chosen based on equivalent quartiles of patient-time. Quartiles of duration of use were also chosen to have intervals with equal numbers of patient-time in each.
Event definition and documentation
For this study, CVE were defined as cardiac death, myocardial infarction, stroke, hospitalisation for hypertension, coronary revascularisation procedures, ventricular arrhythmia, unstable angina, congestive heart failure, transient ischaemic attacks, deep vein thrombosis (DVT), peripheral arterial thromboembolic event, urgent peripheral arterial revascularisation, peripheral arterial ischaemia, pulmonary embolism (PE), acute coronary syndrome or ‘other’ event. ‘Other’ events included complex or overlapping events, other arrythmias or conduction abnormality, cardiomyopathy, unspecified coronary artery disease, or events the reporting physician felt more comfortable categorising as ‘other’ if there was potential overlap with category choices provided.
At follow-up visits, both physician and patient-derived clinical data were updated in detail, including medication and dose changes for GC and cs/ts/bDMARDs.22 Incident comorbidities and targeted medical events, including CVE, were specifically ascertained and collected at each visit by the treating rheumatologist (see online appendix file 1). After the receipt of a report of CVE on the registry form, the site then completed a separate e-form with deidentified primary hospital or cardiologist records confirming and validating the event with description of specific drugs and dose used for treatment (see online appendix efigure 2).24 These forms were reviewed to confirm and validate the event, and ensure that it had not been previously reported, with any duplicate events excluded. In addition, a physician could report an event between formal registry visits. Finally, CVE, in particular CV death, were also reported on registry exit form. Any event that was not confirmed and validated was excluded.
The registry enrolment visit date was the index date. Only the first CVE following enrolment was used. Missing data for covariates were carried forward from the prior visit. If missing GC dose at a visit occurred, the prior dose was carried forward.
Time to first CVE was modelled using Cox proportional-hazards regression models to estimate unadjusted and adjusted HR and 95% CIs. Our model computed cumulative dose or duration of use over the preceding 6 months or 1 year at every daily time point from the index date to the last time point for each patient. This last time point could be a CVE, last registry visit, or dropout from the registry, whichever occurred first. At each time point, the model compared the risk of a CVE in patients at each quartile of prednisone use (current dose, cumulative dose, duration of use) to the risk in patients with no use.
For the adjusted analysis, baseline covariables in the model included age, sex, race, duration of RA, history of CV disease, diabetes mellitus, hyperlipidaemia, hypertension, statin use, NSAID use, tobacco use, year of enrolment, baseline modified Health Assessment Questionnaire score (mHAQ) and the baseline Clinical Disease Activity Index (CDAI) for RA. The CDAI is a validated disease activity metric that includes tender and swollen joints (28 joint count), as well as physician and patient evaluation of global arthritis activity on a 10-point Visual Analogue Scale.25 Additionally, time-varying covariates in the model included measures of prednisone use as described above, NSAID use, cs, b, tsDMARDS and CDAI, which were updated at each follow-up visit.
A sensitivity analysis excluded all venous thromboembolisms (DVT and/or PE) as CVE to determine if excluding venous events impacted risk. A different sensitivity analysis excluded all patients with prior history of a CVE to assess whether this comorbidity had influenced risk. Another sensitivity analysis excluded ‘other’ CVE to assess its influence on the outcomes of interest.
Student’s t-test or χ2 test compared data at baseline. All analyses were generated using Stata V.16.1 (StataCorp).
A total of 19 902 patients (41%) met entry criteria. Exclusions occurred as follow: 21 162 patients had prior history of prednisone use; 5059 patients had no follow-up; 42 patients were missing information regarding use of prednisone; 1672 patients had time between visits of >15 months; 743 patients had missing information for covariates (age, gender, duration of RA, smoking status, CDAI and/or mHAQ).
For the 19 902 who met criteria, the follow-up included 66 436 patient-years and 127 674 follow-up visits over >16 years. Of these patients, 2500 (12.6%) initiated GC during the follow-up. Median time to first use in the registry was 19 months (IQR: 9.1–38.4) after enrolment.
Assessment of CVE risk with initiating GC use
A total of 1106 CVE occurred, yielding a rate of 1.66 CVE per 100 patient-years (95% CI 1.57 to 1.77). As depicted in table 1 of unadjusted enrolment characteristics prior to any CVE and follow-up interval, patients who developed CVE had a greater prevalence of traditional CV risk factors, more severe RA, and were more likely to use csDMARD. Table 2 displays the frequency of each CVE.
Table 3 displays unadjusted and adjusted HR for daily and cumulative dose and duration of GC use over the preceding 6 month and 1 year intervals. Online appendix table 1 shows the number of patients contributing time to each category. Unadjusted current daily dose of <5 mg was not associated with increased risk, while doses ≥5 mg increased risk in a dose-response manner. Figure 1 demonstrates the adjusted risk of CVE based on daily prednisone-equivalent dose with similar findings.
As shown in table 3, cumulative doses of >750 mg over the preceding 6 months were associated with increased unadjusted risk for developing a CVE. Figure 2 shows the risk for developing a CVE remained for cumulative doses of >750 mg after adjustment for covariates. In both unadjusted and adjusted analyses, cumulative doses ≤750 mg were not associated with increased risk. Also shown in table 3, cumulative doses of >1110 mg over the preceding 1 year were associated with significant increased unadjusted risk for developing a CVE. Figure 2 shows this risk remained for cumulative doses of >1100 mg after adjustment for covariates. In both unadjusted and adjusted analyses, cumulative doses ≤1100 mg over the preceding 1-year were not associated with increased risk.
As shown in table 3, GC use for >80 days over the preceding 6 months interval was associated with increased unadjusted risk for developing a CVE. Shorter use than 80 days was not associated with increased risk. Figure 3 illustrates similar risk when adjusted for covariates. Over the preceding 1-year interval, a similar, if less smooth, increased unadjusted (table 3) and adjusted (figure 2) risk for a CVE after 100 days of use was found.
Online appendix table 2 shows the results of the sensitivity analysis when DVT and PE were excluded. With exclusion of DVT/PE, 1007 CVE occurred. Results were similar to the primary analysis.
Online appendix table 3 shows the results of the sensitivity analysis when a history of prior CVE was excluded. With this exclusion, the total number of patients was 18 168, with 2300 initiating prednisone. There were 829 CVE in this analysis. Results were similar to the primary analysis.
Online appendix table 4 shows the results of the sensitivity analysis when ‘other’ CVE were excluded. With this exclusion, 817 events occurred. The results were similar to the primary analysis.
We report, for the first time, that the relative cardiovascular safety or risk of initiating GC in a real-world clinical sample of steroid-naïve RA patients with longstanding disease at registry enrolment is associated with a threshold daily dose, cumulative dose, and duration of use when analysed over short-term intervals of the preceding 6 months or 1 year. The risk for CVE increased directly with increasing current daily dose, with the greatest estimated risk at ≥5–9 mg and ≥10 mg of prednisone-equivalents. Similarly, the risk for CVE increased in a dose-response manner with increasing cumulative dose over these short-term intervals of analysis. The risk for CVE based on duration of use found increased risk after 80-days of use over the preceding 6 months and 100-days over the preceding 1 year in the dose ranges reported. There is ‘noise’ in the duration of use data, especially over the preceding 1 year, and it is possible that this is due to a threshold effect related to dose. That is, the duration of use analysis does not necessarily account for dose; thus, similar durations of use may have different total doses, especially with longer use. Of additional clinical importance, we found no increased risk for CVE with current prednisone-equivalent daily doses of <5 mg or cumulative doses of ≤750 mg over the preceding 6 months or ≤1100 mg over the preceding 1 year. We found no increased risk with duration of use ≤80 days over the preceding 6 months or ≤100 days over the preceding 1 year. It is critically important to note that these findings remained after adjustment for established cardiovascular risk factors, RA duration, disease activity and cs/ts/bDMARDs.
These novel insights can be immediately employed in clinical practice. The methodology of our analysis allows the application to patients based on their most recent 6 months or 1 year GC use. We believe that our data demonstrate that GC use should be tapered to a dose of <5 mg prednisone-equivalents as expeditiously as possible, while being aware of duration of use and cumulative dose. Thus, clinicians should provide counselling and education of these findings when encountering a reluctance on the part of a pain-free patient to taper GC, or succumb to the temptation to simply increase the dose to make the patient feel better until their next visit.
Both the IMPROVED and CareRA trials established that GCs can be tapered in patients with early RA in a protocolised, supervised, investigational regimen.26 27 Verschueren et al also reported on a supervised step-down GC taper in 19 patients with early RA.28 The observational data we report on in patients with longstanding disease are perhaps more representative of a general population of RA patients on GC.
It should also be noted that we stratified our subject sample to see how subjects who developed CVE differed at the baseline time of registry enrolment from those who did not (table 1). Those who developed CVE were older, had more traditional CVD risk factors, greater disease activity, longer disease duration, and more commonly were on non-bDMARDs. Again, adjustment for these factors found an independent association with GC use.
The methodology of our investigation expands on the prior literature. Both Saag et al and Davis et al studied adverse events, including CVE, in RA patients receiving GC.7 10 However, there are numerous differences in methodology of the present investigation including the historical therapeutic interval and duration of observation,10 robustness of numbers, as well as specific focus on CVE. Our adjustment for multiple confounding variables further distinguishes our approach from prior studies that did not adjust for all these variables.8 9 29–32 Our findings provide context beyond these prior studies by highlighting the relative cardiovascular safety of doses of GCs ≤4 mg daily over the 6-month interval described.18 33 Our findings also add evidence to the EULAR and ACR task force recommendations for steroid taper.19 34 Huscher et al also reported a threshold for GC side effects in RA patients without examining CVE.35
Others have looked at the effects of short-term GC use. George et al reported on the effect of dosages on serious infectious events (SIEs) using a Medicare claims database.36 They found a robust relationship of SIEs with increasing doses, although they were not able to determine the effect of actual disease activity. Similarly, Yao et al used a national insurance database to assess the effects of short ‘burst’ courses (≤14-days) of prednisone on incident adverse events of gastrointestinal (GI) bleeding, sepsis, and heart failure at 5–30 days and 31–90 days from use, finding a higher incidence rate of these events at both time points in the general population who used prednisone.37 Together, the findings of these studies of predominantly non-cardiac adverse events support our conclusion that detrimental effects of GC are strongly associated with short-term intervals preceding the event.
Our study has several additional strengths. Our investigation spanned a 16-year period, while prior studies were based much shorter duration of observation.8 9 29–32 38–40 The data were derived from over 700 participating sites of real-world clinical observation in the USA The protocol independently confirmed and validated events with hospital records. We then analysed reported events, not limiting to MACE, increasing the real-world clinical relevance for practising physicians. We excluded prevalent and past GC users, in an effort to minimise the effect of past use. Sensitivity analyses demonstrated that having a history of prior CVE, venous-related events, or the ‘other’ category of CVE did not influence the results, a particularly important design feature of our analysis.41 42
Our study is not without limitations. Patients in observational registries are treated without assignment of interventions. Although we adjusted for multiple confounding factors, there is still a risk of channelling bias or residual confounding. While GC dose and usage were updated in the registry at each visit, there is potential for patient reporting to be limited by recall bias. However, the percentage of patients we studied without prior GC use at the time of registry enrolment (41%) is similar to that reported in the ARAMIS registry, supporting our robust data collection methods.43 It is not clear whether our findings are applicable to early RA patients treated with GC since our cohort contained predominantly RA patients with longer disease duration. A similar observational analysis of the success of GC taper in early RA patients not participating in a supervised protocol would be of interest.
A possible limitation of this report is that we were not able to adjust our findings for time-varying changes in C reactive protein, which is a known risk factor for CVE, or for either rheumatoid factor or anticitrullinated protein antibody status as laboratory values are not mandated in this observational registry. However, we adjusted for other traditional cardiovascular risk factors, as well as time-varying changes in actual RA disease activity measured at the time of each registry visit. As is the case with long-term observational data, the cohort of patients at different time points may differ as patients enter and exit the registry. The risk was established with a very large number of patients over very long observational intervals that greatly increased our statistical power. Nevertheless, assignment of risk to a specific individual may not be appropriate. In addition, with any statistical association, we cannot determine causality with absolute certainty. While a prospective randomised controlled trial of GC dosing would be ideal, it is highly unlikely that this kind of trial will ever be conducted given the pragmatic challenges with the number of patients required, study duration, funding, ethics, and other challenges associated with the complete absence of steroid use in a control group.
In conclusion, we reported that daily doses of ≥5 mg of prednisone-equivalents, elevated cumulative dose and extended duration of use of GC over the preceding 6-month and 1-year intervals are associated with an increased risk for incident CVE in steroid-naïve patients with RA. We also emphasise the relative absence of CVE with dosing of ≤4 mg per day, lower cumulative dose and a duration of use of only 6 months prior to an event. Physicians treating patients with RA should consider these threshold ranges of GC use when prescribing prednisone as a part of a treat-to-target regimen.
Data availability statement
Data may be obtained from a third party and are not publicly available. Deidentified participant data may be obtained from CorEvitas (formerly Corrona) and are not publicly available. Reuse only with permission from CorEvitas. Contact: email@example.com
Patient consent for publication
New England Institutional Review Board, ID number 120160610. All patients gave written informed consent.
Disclaimer : This is a summary of a scientific article written by a medical professional (“the Original Article”). The Summary is written to assist non medically trained readers to understand general points of the Original Article. It is supplied “as is” without any warranty. You should note that the Original Article (and Summary) may not be fully relevant nor accurate as medical science is constantly changing and errors can occur. It is therefore very important that readers not rely on the content in the Summary and consult their medical professionals for all aspects of their health care and only rely on the Summary if directed to do so by their medical professional. Please view our full Website Terms and Conditions.
Copyright © 2021 BMJ Publishing Group Ltd & European League Against Rheumatism. Medical professionals may print copies for their and their patients and students non commercial use. Other individuals may print a single copy for their personal, non commercial use. For other uses please contact our Rights and Licensing Team.
Handling editor Josef S Smolen
Contributors AJO and JMK designed the study. Statistical analysis by GR. All authors (AJO, GR, DAP, JRC and JMK) participated in data interpretation, writing, editing and final approval.
Funding The investigation was funded by the Corrona Research Foundation, a not for profit, 501(C)(3) independent charitable foundation, with no industry financial ties
Competing interests AJO has no financial conflicts of interest. GR and JMK are consultants for Corrona, LLC. GR is a consultant for the Corrona Research Foundation (CRF), while JMK is an officer of the CRF who serves without any form of remuneration. The CRF is a not for profit, 501(C)(3) independent charitable foundation, with no industry financial ties. DAP is an employee and shareholder of Corrona, and a consultant for Regeneron, Novartis and Roche (unrelated work), and is a member of the board of directors for CFR. JRC has research grants and/or consulting from Abbvie, Amgen, Corrona, Janssen, Lilly, Pfizer, Sanofi (for unrelated work).
Patient and public involvement statement Patients were involved upon signing informed consent to participate in the registry, understanding that information would be recorded longitudinally and used for a variety of research outcomes that could be relevant to care. Patients were informed about the time required to complete forms at each visit. Outcomes of CorEvitas studies are shared with patients when viewed as potentially impacting their welfare. Patients were not involved in the design of or recruitment for this study.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.